Another large insurer has said it will cover Cologuard, a stool-based DNA screening test for colorectal cancer developed by Madison, WI-based Exact Sciences. The announcement sent the company’s stock price higher during trading Monday.
Hartford, CT-based Aetna (NYSE: AET) updated its policy to include Cologuard in its list of covered colorectal cancer screening tests on Friday, according to a research note by Doug Schenkel, an analyst at Cowen and Company. Aetna said in 2015 that it would cover Cologuard for members of its Medicare Advantage plan, but this is the first time the insurer has said it would cover Cologuard for its estimated 18.6 million commercial, or non-Medicare, patients. Read the full story here.